Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma

Multiple myeloma and non-Hodgkin’s lymphoma remain the most common indications for high-dose chemotherapy and autologous peripheral blood stem cell rescue. While a CD34+ cell dose of 1 × 10(6)/kg is considered the minimum required for engraftment, higher CD34+ doses correlate with improved outcome....

Descripción completa

Detalles Bibliográficos
Autores principales: Pelus, Louis M, Farag, Sherif S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781755/
https://www.ncbi.nlm.nih.gov/pubmed/24198526
http://dx.doi.org/10.2147/SCCAA.S6713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781755/
https://www.ncbi.nlm.nih.gov/pubmed/24198526
http://dx.doi.org/10.2147/SCCAA.S6713

Ejemplares similares